MARLBOROUGH, Mass., Sept. 15, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, today announced that Dr. Geert Cauwenbergh, RXi's President and CEO, will be participating in the upcoming 15th Annual Biotech in Europe Forum for Global Partnering and Investment Conference, with an oral presentation and panel discussion. This Forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life sciences industry.

Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO

On Tuesday, September 29, 2015 from 12:00 to 1:00 p.m. CEST, Dr. Cauwenbergh will discuss the development and partnering strategy for RXi's proprietary self-delivering RNAi (sd-rxRNA®) platform during a panel discussion entitled Platform Technologies & Novel Therapeutics

In addition, on that same day at 3:15 p.m. CEST, Dr. Cauwenbergh will present a corporate overview that includes multiple business development opportunities available based on RXi's proprietary sd-rxRNA® platform and extensive intellectual property portfolio. The presentation will be available on the Company's website at www.rxipharma.com approximately one hour after the presentation.

About the 15th Annual Biotech in Europe Forum

The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. This meeting is being held September 29-30, 2015 at the Congress Center in Basel, Switzerland.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology that address high-unmet medical needs. Our discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents. These compounds include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA®) compounds for the treatment of dermal and ocular scarring. It also includes an immunomodulator, Samcyprone, a proprietary topical formulation of diphenylcyclopropenone (DPCP), for the treatment of disorders such as alopecia areata, warts, non-malignant skin tumors and cutaneous metastases of melanoma.

RXi's novel, self-delivering RNAi (sd-rxRNA®) compounds are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. sd-rxRNAs have been shown, in vitro and in vivo, to achieve efficient spontaneous cellular uptake and potent, long-lasting intracellular activity. 

RXI-109, an sd-rxRNA compound, is the Company's first clinical development candidate. RXI-109 silences Connective Tissue Growth Factor (CTGF), which plays a key role in tissue regeneration and repair and is initially being developed to reduce or inhibit scar formation in the skin and in the eye. RXI-109 is currently being evaluated in Phase 2a clinical trials in dermatology and a Phase 1/2 trial is planned to initiate this year in ophthalmology. The Company's sd-rxRNA technology platform is broadly protected by multiple issued patents and numerous patent applications.

RXi's robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest. Additional information may be found on the Company's website, www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors." Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-15th-annual-biotech-in-europe-forum-for-global-partnering-and-investment-conference-300142798.html

SOURCE RXi Pharmaceuticals Corporation

Copyright 2015 PR Newswire

RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more RXI Pharmaceuticals Corporation Charts.
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more RXI Pharmaceuticals Corporation Charts.